United Therapeutics (UTHR) Return on Capital Employed (2010 - 2026)

United Therapeutics (UTHR) has 17 years of Return on Capital Employed data on file, last reported at 21.43% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 89.0% year-over-year to 21.43%; the trailing twelve-month figure through Mar 2026 stood at 21.43% (up 89.0% YoY), and the FY2025 full-year result was 21.14%, up 4.0% from the prior year.
• Return on Capital Employed rose to 21.43% in Q1 2026, from 21.16% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 51.39% in Q3 2024 to a low of 16.63% in Q1 2023.
• A 5-year average of 22.81% and a median of 19.84% in 2025 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed jumped 3338 bps in 2024 and slumped 3031 bps in 2025, its largest moves.
• Tracing UTHR's Return on Capital Employed over 5 years: stood at 17.59% in 2022, then grew by 7 bps to 18.84% in 2023, then surged by 148 bps to 46.75% in 2024, then plunged by 55 bps to 21.16% in 2025, then gained by 1 bps to 21.43% in 2026.
• Business Quant data shows UTHR's Return on Capital Employed at 21.43% in Q1 2026, 21.16% in Q4 2025, and 21.08% in Q3 2025.